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Abstract
Stimulation of HEL megakaryocytic cells by Fcg RIIA crosslinking is associated with tyrosine phosphorylation of syk
 . 2qand phospholipase C g 2 PLCg 2 and is accompanied by formation of inositol phosphates and release of intracellular Ca .
These responses are inhibited by the kinase inhibitors, staurosporine and ST271. In contrast, the G-protein receptor agonist,
thrombin induces formation of inositol phosphates and release of intracellular calcium without an increase in tyrosine
 .phosphorylation. The plant lectin wheat germ agglutinin WGA stimulates tyrosine phosphorylation of syk and PLCg 2 but
surprisingly does not stimulate formation of inositol phosphates and induce release of intracellular Ca2q. WGA also
inhibited formation of inositol phosphates and release of intracellular Ca2q by Fcg RIIA crosslinking and thrombin-stimula-
tion. A similar inhibitory effect of WGA was observed against elevation of Ca2q by the same two stimuli in MEG-01
megakaryotic cells. The results demonstrate a novel pathway of inhibition of PLC on crosslinking of cell surface proteins
that is not present in platelets.
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1. Introduction
 .Human erythroleukemia cells HEL are derived
from the peripheral blood of a patient with Hodgkin’s
w xdisease who later developed erythroleukemia 1 . HEL
cells express markers for erythrocytes, myelomono-
Abbreviations: BSA, bovine serum albumin; Fcg RIIA, platelet
low affinity IgG receptor of Fcg RIIA; EDTA, ethylenediamine
 .tetraacetic acid; EGTA, ethyleneglycol bis b-aminoethyl ether -
N, N, N X, N X tetra acetic acid; GP, glycoprotein; HEL, human
erythroleukemia cell; ITAM, immunoreceptor tyrosine-based ac-
tivation motif; PLC, phospholipase C; PMSF, phenylmethyl-
sulphonyl fluoride; SDSrPAGE, sodium dodecyl sulphaterpoly-
acrylamide gel; TBS-T, Tris-buffer saline containing Tween-20;
WGA, wheat germ agglutinin
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w xcytes, B lymphocytes and platelets 1 . In addition,
they express various plasma membrane receptors
which are found on human platelets including the
w xfibrinogen receptor, the integrin a -b 2 , andIIb 3
respond to many platelet agonists including a -2
w x w xadrenergic stimuli 3 , thromboxane A 4 , thrombin2
w x w x5 , ADP 6 and immune complexes which activate
w xthe low affinity Fc receptor, Fcg RIIA 7 . MEG-01 is
a megakaryoblastic cell line from a patient with blast
crisis, which expresses Fcg RIIA and platelet integrin
w xa -b 8 .IIb 3
Signalling by the Fcg RIIA receptor shares many
features with those of other immune receptors like T-
and B-cell antigen receptors. These immune receptors
have an immunoreceptor tyrosine-based activation
motif ITAM; previously known as ARAM, TAM
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. w xand ARH1 9,10 . The ITAM sequence is YXXLrI-
X -YXXLrI single amino acid code; Xsany6-8
.amino acid , with the exception of Fcg RIIA where
there are twelve amino acids between repeating
YXXL regions. Activation of Fcg RIIA in U937
monocytic leukaemia cells and neutrophils leads to
an increase in intracellular Ca2q and tyrosine phos-
w xphorylation of PLCg1 11–13 . In platelets, cross-
linking of Fcg RIIA causes tyrosine phosphorylation
w xof PLCg 2 14 leading to formation of inositol phos-
phates and elevation of intracellular Ca2q.
Considerable evidence supports a model whereby
crosslinking of the antigen receptor leads to phospho-
rylation of the ITAM, probably by a member of the
src family of tyrosine kinases, thereby forming a
docking site for the tandem SH2 domains of the
w xtyrosine kinases syk and zap-70 15,9 . This in turn
initiates a series of events which lead to tyrosine
phosphorylation of syk and zap-70 and subsequently
PLCp g1 andror g 2. The importance of tyrosine
phosphorylation of syk and zap-70, and the role of
other proteins in regulating tyrosine phosphorylation
of the PLCg isoform is not established.
Evidence for a role of syk in signalling by Fcg RIIA
w xhas been obtained in HL-60 cells 16 , THP-1 cells
w x w x w x17,18 , macrophages 19 and platelets 20 . Syk is
also implicated in signalling by several receptor stim-
uli in platelets which do not belong to the family of
immune receptors. We have proposed that the extra-
cellular matrix protein collagen regulates syk through
an ITAM containing protein that is associated with its
cell surface receptor. In support of this, we have
recently identified the presence of the ITAM-contain-
ing Fc receptor g chain in platelets and have shown
that this undergoes tyrosine phosphorylation follow-
ing stimulation by collagen but not by the G protein
w xagonist thrombin 21 . It is speculated that the Fc
receptor g chain underlies regulation of syk by colla-
gen. The cell surface receptor which recognises colla-
gen and lies upstream of the Fc receptor g chain is
not known. WGA also stimulates tyrosine phosphory-
lation of syk in platelets in associated with phospho-
w xrylation of the Fc receptor g chain and Fcg RIIA 21 .
It is proposed that WGA stimulates activation by
crosslinking of receptors for collagen and immune
complexes.
In order to establish a cell line model which can be
used to further investigate the regulation of PLCg 2
by platelet stimuli, we investigated the effect of
platelet agonists on immortalised cell lines exhibiting
features characteristic of megakaryocytes. In the pres-
ent manuscript, we report results of investigations on
two cell lines, HEL and MEG-01, which express
several platelet specific markers including the fib-
rinogen receptor, integrin a -b . Crosslinking ofIIb 3
Fcg RIIA in HEL cells causes formation of inositol
phosphates, a rise in intracellular Ca2q and tyrosine
phosphorylation of syk and PLCg 2. In contrast,
crosslinking of cell surface glycosylated proteins by
WGA, causes tyrosine phosphorylation of syk and
PLCg 2 but without formation of inositol phosphates
and elevation of intracellular Ca2q. Moreover, WGA
inhibits activation of PLC and elevation of Ca2q
induced by Fcg RIIA or the G protein-coupled recep-
tor agonist, thrombin. The results demonstrate the
existence of an inhibitory pathway of signalling which
is activated by crosslinking of a glycosylated cell
surface protein.
2. Materials and methods
2.1. Materials
The anti-phosphotyrosine monoclonal antibody
 .mAb , 4G10, was purchased from Upstate Biotech-
 .nology Inc. TCS Biologicals, Bucks., UK . The
mAb IV.3, specific for Fcg RII, was purchased from
 .Medarex Inc. NJ, USA . An anti-syk rabbit poly-
 .clonal antibody ‘syk LR ’ raised against a polyhisti-
dine fusion protein containing amino acids 257–352
within the linker region of syk was purchased from
 .Santa Cruz CA, USA ; a second rabbit polyclonal
antibody to syk, was raised against a peptide se-
quence within the tyrosine kinase domain
 .CRADENYYKAQTHG , was purchased from Wako
 . w xChemicals GmbH Neuss, Germany 22 . Rabbit an-
tiserum against residue 461–481 and 1218–1239 of
w xPLCg 2 was prepared as described 23 and was a
kind of gift of Dr. Young Han Lee. Polyvinylidene
 .difluoride PVDF membrane was from BioRad
 .Herts., UK . Collagen was from Horm Chemie
 .Munich, Germany . Tween-20, protein A-sepharose
 X.CL 4B, staurosporine, thrombin, sheep IgG F ab 2
raised against mouse IgG and WGA were purchased
 .from Sigma Poole, Dorset, UK . ST271 was a gift
( )E. Rezaei et al.rBiochimica et Biophysica Acta 1356 1997 101–110 103
 .from the Wellcome Foundation Beckenham, UK .
 .Nonidet P-40 NP-40 and Dowex Anion Exchange
 . Resin AG1x8 were purchased from BDH Poole,
.  .Dorset, UK . Horseradish peroxide HRP -conjugated
 .sheep anti- mouse IgG , Horseradish peroxide
 .  .HRP -conjugated donkey anti- rabbit IgG , enhanced
 .chemi luminescence ECL reagents, and Hyperfilm
 .were from Amersham International Cardiff, UK .
3  .H-myo inositol spec. act. 23.4 Cirmmol were
from New England Nuclear-DuPont Stevenage, Bed-
.fordshire, UK . Fura2-AM was obtained from Cal-
 .biochem Nottingham, UK . RPMI, glutamine, peni-
cillin-streptomycin and foetal calf serum were from
 .Gibco Paisley, UK . HEL and MEG-01 cells were
obtained from The American Tissue Culture Corpora-
 .tion Rockville, MD, USA . All other reagents were
of analytical grade.
2.2. Methods
2.2.1. Cell preparation and stimulation
HEL and MEG-01 cells were cultured in RPMI
medium with 2 mM glutamine, penicillin-strepto-
 .  .mycin 1% , and foetal calf serum 10% . The cells
were used at a density of between 0.5–1.5=106
cellsrml in a humidified atmosphere of 5% CO at2
378C. Cells were removed from growth medium by
centrifugation at 470=g for 10 min. The pellet was
resuspended in Hank’s buffer composition: 143 mM
NaCl, 5.6 mM KCl, 10.0 mM Hepes, 1.3 mM CaCl ,2
.2.0 mM MgCl , 10 mM glucose, pH 7.2 . Fcg RIIA2
was stimulated by cross linking with mAb IV.3 1
.  X.  .mgrml and F ab anti-mouse IgG 30 mgrml :2
 X.mAb IV.3 was added 60 s before F ab , the latter2
time being taken as the start of stimulation. The
protein kinase inhibitors staurosporine and ST271
were given 60 s before agonist stimulation.
2.2.2. Measurement of intracellular free calcium
Cells were suspended in Hank’s buffer as de-
 .scribed above and incubated with Fura2-AM 3 mM
in a shaking water bath for 30 min at 378C. After the
incubation, cells were centrifuged at 470=g for 10
min and resuspended at a concentration of 2.5–7.5=
5  .10 cellsrml. Aliquots 500 ml of cells were trans-
ferred to a semi-cuvette and fluorescence determined
at two excitation wavelengths of 340 and 380 nm and
the emission wavelength of 510 nm. The ratio of the
signal at the two excitation wavelengths gives the
Ca2q concentration using the formula of Grynkiewicz
w xet al. 24 . Fmax and Fmin were measured following
 . 2qlysis with Triton-X-100 3% in the presence of Ca
 .  .1 mM and EGTA 10 mM containing 100 mM
Tris-base, pH: 7.2, respectively. Stirring was carried
out throughout the experiment.
2.2.3. Measurement of inositol phosphates
Cells were grown in the presence of 1 mCirml
3H-myo-inositol for 48 h. On the day of an experi-
ment, cells were removed from growth medium by
centrifugation at 470=g for 10 min and resuspended
in Hank’s buffer. Cells were preincubated with LiCl
 .10 mM at 378C for 5 min before agonist addition
and left for a further 5 min. Reactions were termi-
nated by adding 940 ml of CHCl :CH OH:HCl3 3
 .100:200:2 vrvrv , followed by 310 ml CHCl and3
310 ml H O. Phases were separated by centrifugation2
 .at 200=g. The upper phase 750 ml , which con-
tains inositol phosphates, was transferred to a Dowex
w3 xanion exchange column and allowed to drain. H in-
w3 xositol and H glycerophosphoinositol were eluted
with 12 ml of 5 mM disodium tetraborater60 mM
w3 xammonium formate. Total H inositol phosphates
were eluted with 6 ml of 800 mM ammonium for-
mater0.1 M formic acid. Radioactivity was measured
w3 xby scintillation counting. Formation of H inositol
phosphates is expressed as a percentage increase
above the basal level. Data are given as percentage of
mean"s.e. mean of n experiments. Results in con-
trol and treated cells were compared using Student’s
 .t-test non-paired with P-0.05 and P-0.01 taken
to indicate significance.
2.2.4. Immunoblotting
Following stimulation, HEL cells were added to an
equal amount of Laemmli buffer, before heating for 5
min at 958C. Proteins were separated by 10%
SDSrPAGE and transferred to PVDF blotting mem-
branes using a semi dry transfer system. Membranes
were incubated for 30 min at room temperature with
10% BSA in TBS-T 20 mM Trisr137 mM
.NaClr0.1%Tween-20, pH 7.6 before probing for 60
min at room temperature with the primary antibody.
Membranes were washed twice in TBS-T and incu-
bated for 60 min with HRP-conjugated sheep anti-
 .mouse IgG as secondary antibody. Membranes were
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washed in TBS-T and treated with ECL reagents
before exposure to ECL-Hyperfilm.
2.2.5. Immunoprecipitation and Immunoblotting
HEL cells were lysed on ice for 10 min with an
equal volume of lysis buffer 2% NP-40, 300 mM
NaCl, 20 mM Tris, 2 mM EGTA, 2 mM EDTA, 5
.mM Na VO , 2 mM PMSF . Detergent insoluble3 4
debris was removed by centrifugation at 13 000=g
for 15 min and the supernatant precleared with 25 ml
of protein A-Sepharose CL 4B except for stimula-
tion of the cells with Fcg RIIA to avoid loss of
.receptor complexes bound to mAb IV.3 which had
been hydrated in TBS-T. Each sample was incubated
 .with 2 mgrml of rabbit- syk antibody or 5 ml of
 .rabbit- PLCg 2-antibody for 60 min before addition
of 25 ml of protein A-Sepharose CL 4B. After a
further incubation of 60 min, the protein A-Sepharose
CL 4B was precipitated by centrifugation at 11 600=
g for 30 s and washed twice with lysis buffer see
.above and TBS-T. Immunoprecipitated proteins were
subjected to 10% SDSrPAGE, transferred to PVDF
membrane and probed as described above. Where
reprobing with a different primary antibody was re-
quired, the initial primary antibody was removed by
washing in TBS-T containing 2% SDS and 5% mer-
captoethanol at 808C for 40 min. Membranes were
washed twice with TBS-T and probed with a differ-
ent antibody as described above.
3. Results
3.1. The effect of tyrosine kinase inhibitors on release
of intracellular Ca2q and formation of inositol phos-
phates induced by Fcg RIIA crosslinking and throm-
bin
Thrombin and Fcg RIIA crosslinking stimulated
w3 xformation of H inositol phosphates and elevated
2q  .intracellular Ca in HEL cells Figs. 1 and 2 .
Fcg RIIA crosslinking elevated Ca2q from a value of
80 nM to approximately 180 nM before returning to
 .  .basal levels by 60 s Fig. 2 . Thrombin 10 Urml
induced a larger peak increase in Ca2q of approx.
350 nM which returned to basal levels by 3 min Fig.
.2 . Formation of inositol phosphates by Fcg RIIA
Fig. 1. The effect of kinase inhibitors on formation of inositol
phosphates induced by Fcg RIIA crosslinking and by thrombin in
 . HEL cells. The effect of staurosporine 10 mM and ST271 300
.  .mM on the formation of inositol phosphates induced by a
 .  X.Fcg RIIA crosslinking using mAb IV.3 1 mgrml and F ab 2
 .  .  .anti mouse IgG 30 mgrml and b thrombin 10 Urml was
examined. HEL cells were incubated with the kinase inhibitors
for 60 s and exposed to the above stimuli for 5 min. The data is
expressed as mean"S.E.M. of the percentage stimulation above
basal of five experiments.
crosslinking was inhibited completely by the non-
selective kinase inhibitors staurosporine and ST271
 .Fig. 1 . In contrast, the two kinase inhibitors potenti-
ated thrombin induced formation of inositol phos-
phates with a more pronounced increase observed in
the presence of staurosporine. Neither kinase in-
hibitors altered the basal level of inositol phosphates
 .not shown . Staurosporine also prolonged the in-
crease in Ca2q elevation in response to thrombin but
inhibited completely the response to Fcg RIIA activa-
 . 2qtion Fig. 2 . The action of ST271 on Ca elevation
was not investigated as this is complicated by the
inhibition of Ca2q entry by this class of inhibitor
w x25 .
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Fig. 2. Staurosporine inhibits elevation of Ca2q induced by Fcg RIIA crosslinking but potentiates the response to thrombin in HEL cells.
 .  .  X. HEL cells, loaded with Fura 2, were stimulated by i Fcg RIIA crosslinking using mAb IV.3 1 mgrml and F ab anti mouse IgG 302
.  .  .  .mgrml or by ii thrombin 10 Urml . Cells were preincubated with staurosporine 3 mM for 60 s as indicated. The results are
representative of 12 experiments.
3.2. Wheat germ agglutinin inhibits acti˝ation of
phospholipase C and mobilisation of Ca2q stimu-
lated by thrombin and Fcg RIIA crosslinking
The lectin WGA crosslinks glycosylated proteins
and has been reported to stimulate tyrosine kinase
w xdependent activation of PLC in platelets 26 . WGA
 .10–100 mgrml , however, had no effect on the
level of inositol phosphates or Ca2q, but markedly
inhibited their elevation induced by thrombin or
Fcg RIIA crosslinking in HEL cells Fig. 3A and
.Table 1 . A maximal inhibitory effect was observed
 .at 100 mgrml of WGA. WGA also inhibited eleva-
Table 1
Inhibitory effect of WGA on Fcg RIIA crosslinking and thrombin
induced formation of inositol phosphates in HEL cells
– Fcg RIIA Thrombin
– 100"5.8% 125"3.91% 215"6.41%
) ))qWGA 105"3.53% 108"5.40% 94.6"8.68%
 .HEL cells pre-exposed to WGA 100 mgrml for 60 s before
addition of agonists. Data is shown as percentage increase in
inositol phosphates"S.E.M. of at least three experiments.
 . Thrombin 10 Urml , Fcg RIIA crosslinking mAb, 1 mgrml;
 X. .F ab , 30 mgrml .2
) P -0.05; )) P -0.01.
tion of Ca2q by Fcg RIIA and thrombin in MEG-01
 .cells Fig. 3B .
3.3. Acti˝ation of HEL cells by Fcg RIIA crosslinking
and by WGA is associated with tyrosine phosphoryla-
tion of multiple proteins including syk and PLCg 2
Fcg RIIA crosslinking induces transient tyrosine
phosphorylation of proteins of 38, 40–50, 72, 115
 .and 138 kDa Fig. 4i . The time-course of phosphory-
lation varies between individual protein bands. For
example, a 38 kDa band exhibited a maximum in-
crease in phosphorylation by 30 s before returning to
basal by 120 s. On the other hand, phosphorylation of
two bands of 115 and 138 kDa peaked at 30 s but
remained elevated for 120 s. A similar increase in
tyrosine phosphorylation was observed in HEL cells
 .stimulated by WGA Fig. 4ii . In contrast, neither
collagen nor thrombin stimulated tyrosine phosphory-
 .lation Fig. 4iii . The two kinase inhibitors stau-
rosporine and ST271 markedly inhibited phosphory-
lation in both basal and Fcg RIIA stimulated HEL
 .cells Fig. 5 .
Candidates for the 72 and 138 kDa phosphopro-
teins are the tyrosine kinase syk and PLCg 2 which
undergo tyrosine phosphorylation in platelets acti-
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Fig. 3. Inhibitory effect of WGA on calcium elevation induced by crosslinking of Fcg RIIA and by thrombin in HEL and MEG-01 cells.
 .  .  .  .A HEL cells and B MEG-01 cells, loaded with Fura 2, were stimulated by i Fcg RIIA crosslinking using mAb IV.3 1 mgrml and
 X.  .  .  .  .F ab anti mouse IgG 30 mgrml or by ii thrombin 10 Urml . Cells were preincubated with WGA 100 mgrml for 60 s as2
indicated. The results are representative of three experiments.
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w xvated by Fcg RIIA crosslinking and collagen 20 .
Immunoprecipitation of syk and PLCg 2 confirmed
that the two proteins undergo tyrosine phosphoryla-
tion in HEL cells activated by Fcg RIIA crosslinking
 .and by WGA Fig. 6ArB and Fig. 7 . The presence
of a 50 kDa protein which co-migrates with Fcg RIIA
was observed in syk immunoprecipitates from both
Fcg RIIA and WGA-stimulated HEL cells Fig. 6A
.and B . Tyrosine phosphorylation of Fcg RIIA in-
duced by crosslinking of itself has been reported in
w xplatelets and HEL cells 20,27 . WGA has been re-
Fig. 4. Time-course of tyrosine phosphorylation induced by
 .various stimuli in HEL cells. HEL cells stimulated by i Fcg RIIA
 .  X.crosslinking using mAb IV.3 1 mgrml and F ab anti mouse2
 .  .  .  .IgG 30 mgrml , ii WGA 100 mgrml and iii thrombin
 .  .Th:10Urml and collagen Col:100 mgrml . The samples were
analysed for protein tyrosine phosphorylation with mAb 4G10, as
 .described in Section 2. The time period of stimulation s is
shown. The results are representative of 3–5 experiments.
Fig. 5. The effect of kinase inhibitors on protein tyrosine phos-
phorylation stimulated by crosslinking of Fcg RIIA in HEL cells.
HEL cells were stimulated by Fcg RIIA crosslinking using mAb
 .  X.  .IV.3 1 mgrml and F ab anti mouse IgG 30 mgrml . The2
 . inhibitory effect of staurosporine SP, 10 mM and ST271 ST,
.300 mM was assessed. The results are representative of three
experiments.
Fig. 6. Phosphorylation of syk induced by WGA and by cross-
linking of Fcg RIIA in HEL cells. HEL cells were stimulated by
 .  .  .A WGA 100 mgrml and B Fcg RIIA crosslinking using
 .  X.  .mAb IV.3 1 mgrml and F ab anti mouse IgG 30 mgrml .2
The first and second lanes in each part of the figure are from
control and stimulated samples, respectively. HEL cell lysates
were immunoprecipitated with an antibody raised against syk as
described in Section 2. Samples were separated by 10% SDS-
PAGE and immunoblotted for tyrosine phosphorylation using
 .mAb 4G10. i An anti-phosphotyrosine immunoblot using mAb
 .4G10 with the arrow indicating the position of syk; ii an anti
syk immunoblot carried out following stripping of the anti-phos-
photyrosine blot.
ported to induce tyrosine phosphorylation of Fcg RIIA
w xin platelets 21 .
4. Discussion
The present study demonstrates that HEL and
MEG-01 cells express Fcg RIIA and thrombin recep-
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Fig. 7. Phosphorylation of PLCg 2 induced by WGA and by
crosslinking of Fcg RIIA in HEL cells. HEL cells were stimu-
 .lated by WGA 100 mgrml and Fcg RIIA crosslinking using
 .  X.  .mAb IV.3 1 mgrml and F ab anti mouse IgG 30 mgrml .2
HEL cells lysates were immunoprecipitated with an antibody
raised against PLCg 2, as described in Section 2. Samples were
separated by 10% SDS-PAGE and immunoblotted for tyrosine
 .phosphorylation using mAb 4G10. i An anti phosphotyrosine
immunoblot using mAb 4G10 with the arrow indicating the
 .position of PLCg 2. ii An anti PLCg 2 immunoblot carried out
following stripping of the anti-phosphotyrosine blot.
tors which are coupled to elevation of intracellular
Ca2q. Thrombin activates PLCb isoforms through a
w xG protein-coupled pathway 28 , while crosslinking
of Fcg RIIA activates PLCg through a tyrosine ki-
w xnase-regulated pathway 13 . Staurosporine, a non
selective tyrosinerserine-threonine kinase inhibitor,
w x29,30 and ST271, a selective tyrosine kinase in-
w xhibitor, 31 can be to used to differentiate between
these agonists. The two kinase inhibitors blocked
formation of inositol phosphates by Fcg RIIA cross-
linking whereas the response to thrombin was poten-
tiated. The inhibitory effect of staurosporine and
ST271 is consistent with a major role for tyrosine
phosphorylation in Fcg RIIA signalling, presumably
through activation of PLCg 2 with subsequent forma-
tion of inositol 1,4,5-trisphosphate and Ca2q mobili-
sation.
Potentiation of thrombin induced PLC activation in
the presence of the two inhibitors suggests that the
action of thrombin is independent of tyrosine phos-
phorylation of PLCg isoforms. This conclusion is
consistent with results in platelets where thrombin
failed to stimulate significant tyrosine phosphoryla-
w xtion of PLCg1 and g 2 26 . The mechanism of
potentiation of the response to thrombin by stau-
rosporine and ST271 is not known, but these results
may indicate an inhibitory role of tyrosine phospho-
rylation. The molecular basis of the greater potentia-
tion by staurosporine relative to ST271 may reflect
the additional inhibition of protein kinase C isoforms
by staurosporine. At the concentration used, stau-
rosporine inhibits all known protein kinase C iso-
forms. Additionally, ST271 but not staurosporine,
blocks Ca2q entry and this is associated with de-
creased formation of inositol phosphates by thrombin
w xin platelets 32 .
One of the earliest events following antigen bind-
ing to antigen receptors is the stimulation of protein
tyrosine kinases leading to activation of PLCg , for-
mation of inositol 1,4,5-trisphosphate and release of
intracellular Ca2q. Immunoprecipitation studies with
a specific antibody showed that the tyrosine kinase
syk is one of the first proteins to undergo phosphory-
lation on tyrosine in HEL cells activated by Fcg RIIA
and WGA. Our results are in agreement with Yanaga
w x w xet al. 20 and Inazu et al. 33 who described the
involvement of syk in platelets activated by Fcg RIIA
crosslinking and WGA respectively. In addition, the
presence of a 50 kDa protein which co-migrates with
Fcg RIIA was observed in both WGA and Fcg RIIA
stimulated cells. Phosphorylation of Fcg RIIA by
w xWGA has previously been reported in platelets 21
and suggests that the lectin induces activation of this
receptor through crosslinking.
It has been reported that collagen, Fcg RIIA cross-
linking and WGA induce platelet activation through
w xtyrosine phosphorylation of PLCg 2 13,26 , distin-
guishing this group of stimuli from those which
induce activation through G-protein dependent path-
ways. This is in agreement with the present observa-
tion of phosphorylation of PLCg 2 but not PLCg1 in
HEL cells stimulated by Fcg RIIA crosslinking or by
WGA. The pattern of tyrosine phosphorylation in-
duced by WGA is similar to that for Fcg RIIA stimu-
lation including stimulation of tyrosine phosphoryla-
.tion of a band which co-migrates with Fcg RIIA
suggesting a similar underlying mechanism. This is
consistent with results in platelets where WGA has
been proposed to induce activation in part through
w xFcg RIIA crosslinking 21 . However, WGA does not
induce formation of inositol phosphates and release
of intracellular Ca2q in HEL cells dissociating tyro-
sine phosphorylation of PLCg 2 from its activation.
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This does not reflect an inhibitory effect of cyclic
nucleotides which may also have been elevated by
.WGA as they do not inhibit activation of PLC in
HEL cells stimulated by Fcg RIIA crosslinking or by
 .thrombin not shown . It is possible that WGA re-
quires a co-receptor to induce activation of PLCg 2 or
that it stimulates tyrosine phosphorylation of the
phospholipase at sites unrelated to its activation;
however, these possibilities seem unlikely in view of
the ability of Fcg RIIA to stimulate phospholipase C
activity. The inhibitory action of WGA appears to
reflect a general inhibitory effect as its also inhibits
responses to Fcg RIIA crosslinking and thrombin. For
example, WGA may stimulate activation of a cell
surface receptor that prevents synthesis or breakdown
of phosphatidylinositol 4,5-bisphosphate. Alterna-
tively, WGA may activate inhibitory pathways spe-
cific to G protein and tyrosine kinase coupled recep-
tors e.g. activation of the tyrosine phosphatase PTP1C
via an immunoreceptor tyrosine-based inhibitory mo-
 .tif ITIM selectively inhibits signalling by antigen
w xreceptors such as Fcg RIIA 34 . A similar inhibitory
effect of WGA is not observed in platelets suggesting
that it does not reflect a universal inhibitory action of
WGA but that it may be due to a cell surface receptor
on megakaryocytes which is absent in the platelets.
This inhibitory pathway may be of importance during
megakaryocyte maturation to prevent unwanted acti-
vation. The cell surface glycoprotein which underlies
the inhibitory action of WGA in HEL cells requires
identification.
The inability of thrombin to stimulate significant
tyrosine phosphorylation in HEL cells, compared to
platelets, could be due to the absence of a critical link
that couples the receptor to tyrosine kinases or the
absence of specific tyrosine kinases e.g. src tyrosine
kinase. Collagen also failed to stimulate significant
tyrosine phosphorylation in HEL cells in contrast to
its action on platelets. Activation of platelets by
collagen shares many features with signalling by
Fcg RIIA crosslinking including tyrosine phosphory-
lation of syk and PLCg 2. The observation that HEL
cells respond to Fcg RIIA crosslinking and that they
express the Fcg receptor chain Mountford, Gibbins
.and Watson unpublished , which couples the collagen
w xreceptor to syk 21 suggests that the lack of response
to collagen may reflect the absence of its cell surface
receptor.
In summary, the present study has demonstrated
that Fcg RIIA crosslinking induces activation of
megakaryocytes through a tyrosine kinase dependent
pathway that appears similar to that described in
platelets. In contrast, the lectin WGA inhibits activa-
tion of HEL cells revealing the existence of an
inhibitory pathway preventing hydrolysis of phospho-
inositides. This pathway may present unwanted acti-
vation of megakaryocytes brought about by cross-
linking of cell surface proteins through contact with
other cellsrforeign surfaces during development.
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